L'Institut Pasteur de Tunis en 2017

1. Institut Pasteur
de Tunis
(IPT)
More than 124 years dedicated to
Public Health
www.pasteur.tn

2. Charles Nicolle, Director General, IPT, 1903 à 1936.
Nobel Prize on medicine, 1928
IPT, 1905
Major discoveries on:
Typhus,
Toxoplasma,
leishmaniasis,
Inapparent disease
Founded in 1893

3. Decision bodies (EPS)
• Administrative Council (16 members)
• Scientific Council : DG + 8 elected members from IPT (+4
internationals)
Institut Pasteur de Tunis
• Biomedical Analysis and Public Health Activities
• Production of therapeutic sera and vaccines
• Research & Development
• Training
• Ethics Committee
• Communication, valorization and technology transfer
• Health and Safety
• Bioressources
• Quality
Committees/offices
Figure 4. IPT’s organizational structure
Mission

4.  Global: 477
 Scientists: 123
Human resourses (2016)
Scientists: 123
Technicians: 107
Administrative
staff: 158
Workers: 89

5. The Institut Pasteur
International Network

6. Biomedical Analysis and
Public Health activities
• 18 laboratories + 2 services (35 biologists): Cover the full array of clinical biology
tests. IPT is recognized for the expertise of some of the laboratories in the
specialized medical biology.
• Several national (rabies, poliomyelitis, measles, bacteria, other) or international
reference centers (for the Eastern Mediterranean Region/WHO: for poliomyelitis
and measles, HPV)
• IPT is a center for vaccination (for the travelers) and a center for rabies treatment
and vaccination (free).

7. Bioproduction activities
• BCG vaccine
-BCG + solvant
- Immune BCG
• Therapeutic sera:
- Anti-scorpions : Androctonus australis, Buthus
occitanus
- Anti-vipera: Cerastes cerastes, Vipera lebetina
- Anti-rabies
7142
2627
6980
56741
9155
82645
4429
1557
4020
59246
9727
78979
6226
2077 0
51276
11364
70943
Sérums
antiscorpionique
Sérums
antivipérins
Sérums
antirabique
Vaccin BCG Immun BCG TOTAL
2014 2015 2016
7142
2627
6980
56741
9155
4429
1557
4020
59246
97
6226
2077 0
51276
Sérums
antiscorpionique
Sérums
antivipérins
Sérums
antirabique
Vaccin BCG Immun
2014 2015 2016

8.  Infectious diseases
 Venoms & toxins
 Genetic diseases and congenital immune deficiencies
 Biotechnology and bioprocesses
 Bioinformatics and Mathematical modeling
 Clinical Epidemiology and Control (including clinical trials)
Research & Development

9. •Intramural: PCI (~ 10%)
•National: MHESR (9 laboratories), CIC…(~ 30%)
•International: (~ 60%)
R&D financial support

10. ANR (Paris, France) R&D
BIO-RAD (Paris, France) Patent strengthening
European Commission (Brussels, Belgium) R&D
Fondation Mérieux (Lyon, France) Euro-Mediterranean Public Health
Information System
Fort Dodge Animal Health Vaccine development and validation
International Atomic Energy Agency
(Vienna, Austria) R&D capacity building and training
Institut Pasteur International Network
(Paris, France) R&D and Public Health Activities (control)
Joint WHO/EMRO-COMSTECH
(Islamabad, Pakistan) R&D
National Institutes of Health (Maryland, USA) R&D, clinical research
North Atlantic Treaty Organization
(Brussel, Belgium) R&D
The New Partnership for Africa’s Development
(Johannesburg, South Africa) R&D
Walter Reed Army Institute Of Research
(USA) Clinical trials (phase II and phase III)
Welcome Trust (London, UK) R&D, training
WHO/EMRO (Cairo, Egypt) R&D for control
World Health Organization TDR
(Geneva, Switzerland) R&D, capacity building, training
Funding agencies Grant category

11. • IPT is affiliated to the
University Tunis El Manar
•Supervision of graduate and
post-graduate students
•Organization of theoretical and
hands-on practice training
courses
Training

12. Diploma defended (2014-2016)
13
70
32
12
0 1
128
10
40
33
3 4 3
93
37
46
26
9 9
1
128
Thèses Mastères PFE/ingénieurat Thèses de
méédecine
Théses de
médecine
vétérinaire
Thèses de
pharmacie
TOTAL
2014 2015 2016
13
70
32
12
0 1
128
10
40
33
3 4 3
93
37
46
26
9 9
1
128
Thèses Mastères PFE/ingénieurat Thèses de
méédecine
Théses de
médecine
vétérinaire
Thèses de
pharmacie
TOTAL
2014 2015 2016
PhD MSc Licence MD DVM PHARM D TOTAL

13. Eastern Mediterranean Regional Training
Centre selected
TDR news item
5 May 2015
The Institut Pasteur de Tunis in Tunis, Tunisia, has been
selected to be the Eastern Mediterranean Regional Training
Centre supported by TDR. This is the sixth and final centre to
be chosen for the TDR network, which is designed to expand
and coordinate training courses across multiple countries,
leading to improved use of health interventions.
Ethics: Adapting and using the World Health Organization’s training on ethics for the Tunisian
environment and improving the skills of the Tunis Institutional Review Board.
Good health research practice: Training trainers and researchers with the TDR good clinical
practice and good clinical laboratory practice courses, as well as the Good Health Research
Practice course.
Implementation research: Beginning implementation research courses using the TDR
implementation research toolkit, and working with TDR and others to develop a massive open online
course (MOOC) on implementation research focused on infectious diseases of poverty.

14. IPT’s publication track record
(2012-2016: 612 publications)
142
Partner countries Citation impact with partner institutions

15. R&I performance
Publications/researcher
%Publications
with International
Collaborations
% cited documents
H-index
Citation Impact
Publications Top %10
% Publicatios with
IndustryCollaborations
Patents/researcher
PCRD/researcher
KT
agreement/researcher
IPT
CRG
IP
IPT IP CRG
Number of permanent staff researchers/2016 123 1131 95
Publications* 572 5763 1183
H-index * 24 99 73
Publications/researcher 4,65 5,10 12,45
Publications Top %10 * 7,69 19,54 26,46
% Cited documents* 64,16 79,77 84,28
Citation Impact* 4,52 14,87 27,92
%Publications with International Collaborations * 56,47 57,9 64,33
% Publicatios with Industry Collaborations* 0,22 2,72 4,06
knowledge transfert and partnership agreements * 30 63 41
Patents 15 1451 34
Patents/researcher 0,12 1,28 0,36
PCRD-Projects (FP7-H2020) 13 142 124
PCRD (FP7-H2020)/researcher 0,11 0,13 1,31
KT agreement/researcher* 0,24 0,06 0,41

16. Figure6. PHINDaccess strategic plan
Our strategic actions for increased R&I